Cardio-oncology: A focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management

Ochsner Journal

Volumn 16, Issue 3, 2016, Pages 250-256

  Domercant, Jean ^a   Polin, Nichole ^b,c   Jahangir, Eiman ^b  

^a Leonard J Chabert Medical Center   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Anthracyclines; Cardiotoxicity; Heart failure; Radiation; Trastuzumab

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RAZOXANE; TRASTUZUMAB;

ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER SURVIVAL; CARDIOLOGY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DEATH; DISEASE SURVEILLANCE; DRUG PROTEIN BINDING; HEART FAILURE; HEART VENTRICLE FAILURE; HUMAN; LYMPHOMA; MORTALITY RATE; NONHUMAN; ONCOLOGY; PARTIAL MASTECTOMY; PATIENT CARE; PATIENT MONITORING; RADIATION INJURY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMALL CELL LUNG CANCER; TREATMENT INDICATION; TREATMENT WITHDRAWAL;

EID: 84988530869     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Hong RA, Iimura T, Sumida KN, Eager RM. Cardiooncology/onco-cardiology. Clin Cardiol. 2010 Dec; 33(12): 733-737. doi: 10.1002/clc.20823.
2. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013 Oct 22; 128(17): 1927-1995. doi: 10.1161/CIR.0b013e3182a88099.
3. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005 Dec 13; 112(24): 3754-3762. doi: 10.1161/CIRCULATIONAHA.105.576850.
4. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov; 91(5): 710-717.
5. Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol. 2014 Mar 1; 32(7): 647-653. doi: 10.1200/JCO.2013.50.3557.
6. Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumabrelated cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2012 Apr; 23(4): 897-902. doi: 10.1093/annonc/mdr348.
7. Hershman DL, McBride RB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2008 Jul 1; 26(19): 3159-3165. doi: 10.1200/JCO.2007.14.1242.
8. Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007 Jul; 18(6): 737-744. doi: 10.1097/CAD.0b013e32803d36fe.
9. Singal PK, Deally CMR, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol. 1987 Aug; 19(8): 817-828. doi: 10.1016/S0022-2828(87)80392-9.
10. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997 Oct; 11(12): 931-936.
11. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 Sep 24; 339(13): 900-905. doi: 10.1056/NEJM199809243391307.
12. Martin E, Thougaard AV, Grauslund M, et al. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 2009 Jan 8; 255(1-2): 72-79. doi: 10.1016/j.tox.2008.10.011.
13. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycininduced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984 Oct 26; 226(4673): 466-468.
14. Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012 Nov; 18(11): 1639-1642. doi: 10.1038/nm.2919.
15. Lyu YL, Lin CP, Azarova AM, Cai L, Wang JC, Liu LF. Role of topoisomerase IIbeta in the expression of developmentally regulated genes. Mol Cell Biol. 2006 Nov; 26(21): 7929-7941. doi: 10.1128/mcb.00617-06.
16. Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013 Mar 21; 368(12): 1154-1156. doi: 10.1056/NEJMcibr1214975.
17. Lyu YL, Kerrigan JE, Lin CP, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007 Sep 15; 67(18): 8839-8846. doi: 10.1158/0008-5472.can-07-1649.
18. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992 Aug 17; 1132(1): 43-48.
19. Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol. 1996 Feb 14; 14(2): 328-331.
20. Deng S, Yan T, Nikolova T, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May; 172(9): 2246-2257. doi: 10.1111/bph.13046.
21. Dempsey KS. Chemotherapy-induced cardiotoxicity in women. Heart Fail Clin. 2011 Jul; 7(3): 427-435. doi: 10.1016/j.hfc.2011.04.004.
22. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005 Oct 20; 353(16): 1734-1736. doi: 10.1056/NEJMe058196.
23. Bartsch R, Wenzel C, Steger GG. Trastuzumab in the management of early and advanced stage breast cancer. Biologics. 2007 Mar; 1(1): 19-31.
24. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2- positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar; 12(3): 236-244. doi: 10.1016/S1470-2045(11)70033-X.
25. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002 Oct 1; 95(7): 1592-1600. doi: 10.1002/cncr.10854.
26. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004 Jan 15; 22(2): 322-329. doi: 10.1200/JCO.2004.01.120.
27. Fiuza M. Cardiotoxicity associated with trastuzumab treatment of HER2þ breast cancer. Adv Ther. 2009 Jul; 26 Suppl 1: S9-S17. doi: 10.1007/s12325-009-0048-z.
28. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15; 344(11): 783-792. doi: 10.1056/NEJM200103153441101.
29. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010 Jul 20; 28(21): 3416-3421. doi: 10.1200/JCO.2009.23.6950.
30. Bowles EJ, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 5; 104(17): 1293-1305. doi: 10.1093/jnci/djs317.
31. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 2008; 31(6): 459-467.
32. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumabassociated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep 1; 25(25): 3859-3865. doi: 10.1200/JCO.2006.09.1611.
33. Halyard MY, Pisansky TM, Dueck AC, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol. 2009 Jun 1; 27(16): 2638-2644. doi: 10.1200/JCO.2008.17.9549.
34. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10; 26(8): 1231-1238. doi: 10.1200/JCO.2007.13.5467.
35. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012 Nov 1; 30(31): 3792-3799. doi: 10.1200/JCO.2011.40.0010.
36. Albanell J, Bellmunt J, Molina R, et al. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis. Anticancer Res. 1996 Mar-Apr; 16(2): 1027-1032.
37. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001 Jun 15; 61(12): 4744-4749.
38. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol. 1999 Oct; 27(10): 1533-1541.
39. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004 Sep 1; 10(17): 5650-5655. doi: 10.1158/1078-0432.ccr-04-0225.
40. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr; 6(4): 443-446. doi: 10.1038/74704.
41. Chien KR. Herceptin and the heart-a molecular modifier of cardiac failure. N Engl J Med. 2006 Feb 23; 354(8): 789-790. doi: 10.1056/NEJMp058315.
42. Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med. 2013 Mar 14; 368(11): 1055-1056. doi: 10.1056/NEJMe1215300.
43. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012 Jul-Aug; 62(4): 220-241. doi: 10.3322/caac.21149.
44. Buchholz TA. Radiation therapy for early-stage breast cancer after breast-conserving surgery. N Engl J Med. 2009 Jan 1; 360: 63-70. doi: 10.1056/NEJMct0803525.
45. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14; 368(11): 987-998. doi: 10.1056/NEJMoa1209825.
46. Marks LB, Constine LS, Adams MJ. Cardiotoxicity of radiation therapy for malignancy. UpToDate. Updated May 20, 2015. http://www.uptodate.com/contents/cardiotoxicity-ofradiation- therapy-for-malignancy?source=search_result& search=radiationþcardiotoxicity&selectedTitle=1~150. Published 2015. Accessed January 1, 2016.
47. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994 Mar; 12(3): 447-453.
48. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation. 2003 Sep 2; 108(9): 1146-1162. doi: 10.1161/01.CIR.0000073597.57414.A9.
49. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009 Jan 1; 27(1): 127-145. doi: 10.1200/JCO.2008.17.2627.
50. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987 Jun; 82(6): 1109-1118.
51. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29; 10: 337. doi: 10.1186/1471-2407-10-337.
52. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991 Sep 15; 68(6): 1221-1229.
53. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer. 1990 Feb 15; 65(4): 870-873.
54. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2006 Oct 7; (4): CD005008. doi: 10.1002/14651858.CD005008.pub3.
55. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998 Nov; 16(11): 3502-3508.
56. Neidhart JA, Gochnour D, Roach R, Hoth D, Young D. A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol. 1986 May; 4(5): 672-677.
57. Henderson IC, Allegra JC, Woodcock T, et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 May; 7(5): 560-571.
58. Bennett JM, Muss HB, Doroshow JH, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol. 1988 Oct; 6(10): 1611-1620.
59. Cardinale D, Colombo A, Sandri MT, et al. Prevention of highdose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 Dec 5; 114(23): 2474-2481. doi: 10.1161/CIRCULATIONAHA.106.635144.
60. Bavry A. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy-PRADA. American College of Cardiology. http://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2015/11/11/12/14/PRADA. Accessed February 4, 2016.
61. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006 Dec 5; 48(11): 2258-2262. doi: 10.1016/j.jacc.2006.07.052.
62. Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013 Sep 1; 167(5): 2306-2310. doi: 10.1016/j.ijcard.2012.06.023.
63. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013 Jun 11; 61(23): 2355-2362. doi: 10.1016/j.jacc.2013.02.072.
64. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 3.0. Arcadia, CA: Children’s Oncology Group; www.survivorshipguidelines.org. Accessed January 4, 2016.
65. Cardinale D, Colombo A, Lamantia G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010 Jan 19; 55(3): 213-220. doi: 10.1016/j.jacc.2009.03.095.